KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for GoodRx Holdings (GDRX) over the last 5 years, with Q2 2025 value amounting to $694000.0.

  • GoodRx Holdings' Other Non Operating Income changed N/A to $694000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year increase of 2609.02%. This contributed to the annual value of -$2.7 million for FY2024, which is 3363.27% up from last year.
  • According to the latest figures from Q2 2025, GoodRx Holdings' Other Non Operating Income is $694000.0.
  • In the past 5 years, GoodRx Holdings' Other Non Operating Income ranged from a high of $694000.0 in Q2 2025 and a low of -$2.7 million during Q3 2024
  • For the 3-year period, GoodRx Holdings' Other Non Operating Income averaged around -$1.5 million, with its median value being -$2.0 million (2023).
  • Examining YoY changes over the last 5 years, GoodRx Holdings' Other Non Operating Income showed a top increase of 2090.91% in 2024 and a maximum decrease of 2090.91% in 2024.
  • Over the past 3 years, GoodRx Holdings' Other Non Operating Income (Quarter) stood at -$2.2 million in 2023, then dropped by 20.91% to -$2.7 million in 2024, then skyrocketed by 126.09% to $694000.0 in 2025.
  • Its Other Non Operating Income was $694000.0 in Q2 2025, compared to -$2.7 million in Q3 2024 and -$2.2 million in Q3 2023.